Screener
Amphastar Pharmaceuticals AMPH PP&E (Net)
PP&E (Net) at other companies
Segments
By geography
Other financials
Where this comes from
Reported directly by Amphastar Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.
The source filing: Amphastar Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:50 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001297184-26-000047
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Income tax refunds and deposits | 2,628 | 17,167 |
| Prepaid expenses and other assets | 11,001 | 13,152 |
| Total current assets | 630,951 | 636,016 |
| Property, plant, and equipment, net | 316,063 | 310,567 |
| Finance lease right-of-use assets | 152 | 221 |
| Operating lease right-of-use assets | 72,911 | 42,931 |
| Goodwill and intangible assets, net | 647,833 | 565,965 |
| Other assets | 33,392 | 31,135 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Amphastar Pharmaceuticals's PP&E (net)?
- Amphastar Pharmaceuticals (AMPH) reported PP&E (net) of $316.06M in Q2 2026.
- How has Amphastar Pharmaceuticals's PP&E (net) changed year-over-year?
- Amphastar Pharmaceuticals's PP&E (net) increased by 1.9% year-over-year, from $310.24M to $316.06M.
- What is the long-term trend for Amphastar Pharmaceuticals's PP&E (net)?
- Over 5 years (2020 to 2025), Amphastar Pharmaceuticals's PP&E (net) has grown at a 3.6% compound annual growth rate (CAGR), from $260.06M to $310.57M.
- What does PP&E (net) mean?
- Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.
Ask your AI about Amphastar Pharmaceuticals's pp&e (net).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude